Correction of organophosphate-induced neuromuscular blockade by diphenhydramine.
Dogs exposed to topical organophosphate (fenthion) developed decreased plasma and muscle cholinesterase activities. After 2 doses were applied (1 week between doses), plasma concentrations declined 80% and muscle cholinesterase activity was reduced by 56%. Decremental responses to repetitive nerve stimulation developed after fenthion administration. Diphenhydramine, but not placebo, corrected the electrical abnormalities caused by organophosphate application, but without altering plasma or muscle cholinesterase activity. Control dogs housed in the same kennel demonstrated a slight decrease (18%) of plasma cholinesterase, which indicates that there may be potential cross contamination. Diphenydramine may be effective in treating organophosphate-induced neuromuscular weakness which is refractory to other forms of therapy.
D000818:Animals; D002802:Cholinesterases / Q000378:metabolism; D004155:Diphenhydramine / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology*; D004558:Electric Stimulation; D004576:Electromyography / Q000662:veterinary; D005284:Fenthion / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D009132:Muscles / Q000201:enzymology; D009469:Neuromuscular Junction / Q000187:drug effects*; D012584:Sciatic Nerve / Q000502:physiology
D004155:Diphenhydramine; D005284:Fenthion; D002802:Cholinesterases